Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	88.38B +62.9%
Revenue (ttm)	17.61B +16.3%
Net Income	1.98B +24.0%
EPS	1.10 +21.6%
Shares Out	n/a
PE Ratio	44.70
Forward PE	32.77
Dividend	0.23 (0.72%)
Ex-Dividend Date	Jul 7, 2026

Volume	11,592,257
Open	33.20
Previous Close	33.20
Day's Range	30.84 - 33.78
52-Week Range	14.45 - 34.86
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 24, 2026

Data Sources Report a data error